Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 790 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06632327RecruitingPhase 3
Comparing treatment timing for stage II-IIIB lung cancer
This trial is for people with a certain type of lung cancer (non-small cell lung cancer) that can be surgically removed. It tests whether it is better to receive treatment before or after surgery to remove the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT06014827RecruitingPhase 2
Targeted radiation and osimertinib for lung cancer with EGFR mutation
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
Duarte, CaliforniaAges 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Anchorage, AlaskaAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Daphne, AlabamaAges 18 years+ - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT07017829RecruitingPhase 2
GT103 plus pembrolizumab for STK11 mutant lung cancer
This trial tests a new drug called GT103 combined with the immunotherapy pembrolizumab (Keytruda) for people with advanced lung cancer that has a specific genetic change (STK11 mutation) and has continued to grow despite prior pembrolizumab treatment. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth.
Buffalo, New YorkAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07476287RecruitingPhase 2
Study of PF08634404 plus chemo for transformed small cell lung cancer
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Duarte, CaliforniaAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT05242965RecruitingPhase 2
STEMVAC vaccine with pembrolizumab for advanced lung cancer
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
Omaha, NebraskaAges 18 years+ - NCT07043608RecruitingPhase 2
Zanzalintinib for kidney cancer that spread to bone
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
San Francisco, CaliforniaAges 18 years+ - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Mobile, AlabamaAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 790 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.